Cannabinoid Receptor 2 Activating Antibodies: A Promising Therapeutic Strategy for Macrophage-Driven Fibro-Inflammatory Diseases
Raghavender Reddy Gopireddy, Dipankar Bhattacharya, Swastik Sen, Monica A. Schwartz, Scott L. Friedman, Richard C. Yu, Toshi Takeuchi, Lauren J. Schwimmer
This paper introduces two novel CB2-specific agonist antibodies that reduce macrophage activation and fibrosis in vitro and an ex vivo liver model.
Molecular Pharmacology · Jan 14, 2026Peer-reviewedPharmacology & Toxicology